title: Long-term persistence of anti-hantavirus antibodies in sera of patients undergoing hemorrhagic fever with renal syndrome and subjects vaccinated against the disease.
abstract: Background China has the highest prevalence of hemorrhagic fever with renal syndrome (HFRS) and accounts for 90% of the total cases worldwide. However, the long-term persistence of anti-hantavirus antibodies in sera of patients with HFRS and subjects vaccinated against the disease remains unclear. The aim of the present study was to investigate the prevalence of anti-hantavirus IgG antibodies in sera of patients with prior HFRS, versus subjects vaccinated against the disease and controls in Shaanxi, China. Methods Six hundred individuals were included in this study. We quantified anti-hantavirus IgG antibodies in HFRS patients (n = 100), vaccinees (n = 200), controls from endemic regions (n = 200), and controls from non-endemic regions (n = 100) in China. Results The median optical density (OD) values (range) were 0.803 (0.008-1.813), 0.075 (0.004-1.565), 0.026 (0-1.179), and 0.015 (0.009-0.118) for HFRS patients, vaccinated subjects, endemic controls, and non-endemic controls, respectively. There was a strikingly significant difference between the HFRS group and each non-HFRS group (p < 0.001). The vaccinated subjects were also significantly different from the endemic controls. The time since the acute phase was correlated with the OD values of the HFRS patients. Conclusions Our study suggests that HFRS patients gain long-lasting protection and that vaccination may be an effective way to stimulate antibody production.
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zheng
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Jing
authors.initials: J
authors.lastname: Wei
authors.affiliation: b Medical Device Testing Center of Shaanxi Province , Xi'an , China.
authors.forename: Bu-Yu
authors.initials: BY
authors.lastname: Zhou
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Yi
authors.initials: Y
authors.lastname: Xu
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Dong
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Lu-Yuan
authors.initials: LY
authors.lastname: Guan
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Ping
authors.initials: P
authors.lastname: Ma
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Peng-Bo
authors.initials: PB
authors.lastname: Yu
authors.affiliation: a From the Shaanxi Provincial Centre for Disease Control and Prevention , Xi'an.
authors.forename: Jing-Jun
authors.initials: JJ
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D019353:Endemic Diseases; D005260:Female; D006476:Orthohantavirus / Q000276:immunology*; D006480:Hemorrhagic Fever with Renal Syndrome / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control / Q000821:virology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014765:Viral Vaccines
keywords: Hemorrhagic fever with renal syndrome; IgG; hantavirus; vaccination